{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Coburn SB"],"funding":["Intramural NIH HHS","NCATS NIH HHS","NIA NIH HHS","NIDA NIH HHS","NCRR NIH HHS","NIAID NIH HHS","NHLBI NIH HHS","NIMH NIH HHS","NIAAA NIH HHS","CIHR","NEI NIH HHS","NIDDK NIH HHS","NIMHD NIH HHS","NCI NIH HHS","NIGMS NIH HHS"],"pagination":["663-670"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8026587"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["87(1)"],"pubmed_abstract":["<h4>Background</h4>Studies suggest lower risk of breast cancer in women with HIV versus without HIV. These estimates may be biased by lower life expectancy and younger age distribution of women with HIV. Our analysis evaluated this bias and characterized secular trends in breast cancer among women with HIV initiating antiretroviral therapy. We hypothesized breast cancer risk would increase over time as mortality decreased.<h4>Setting</h4>Women with HIV prescribed antiretroviral therapy in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) from 1997 through 2016.<h4>Methods</h4>We estimated breast cancer hazard (cause-specific hazard ratios) and cumulative incidence accounting for competing risks (subdistribution hazard ratios) to assess changes in breast cancer risk over time. This was assessed overall (1997-2016) and within/across calendar periods. Analyses were adjusted for race/ethnicity and inverse probability weighted for cohort. Cumulative incidence was graphically assessed by calendar period and race/ethnicity.<h4>Results</h4>We observed 11,587 women during 1997-2016, contributing 63 incident breast cancer diagnoses and 1,353 deaths [73,445 person-years (median follow-up = 4.5 years)]. Breast cancer cumulative incidence was 3.2% for 1997-2016. We observed no secular trends in breast cancer hazard or cumulative incidence. There were annual declines in the hazard and cumulative incidence of death (cause-specific hazard ratios and subdistribution hazard ratios: 0.89, 95% confidence interval: 0.87 to 0.91) which remained within and across calendar periods.<h4>Conclusions</h4>These findings contradict the hypothesis of increasing breast cancer risk with declining mortality over time among women with HIV, suggesting limited impact of changing mortality on breast cancer risk. Additional inquiry is merited as survival improves among women with HIV."],"journal":["Journal of acquired immune deficiency syndromes (1999)"],"pubmed_title":["Secular Trends in Breast Cancer Risk Among Women With HIV Initiating ART in North America."],"pmcid":["PMC8026587"],"funding_grant_id":["K01 AI131895","K24 DA000432","UL1 TR002378","U01 AI038858","U01 HL146205","U01 HL146204","KL2 TR000421","U01 AI038855","U01 HL146203","R01 DA011602","U01 HL146208","U01 HL146242","R01 AA016893","U01 AI068636","U01 HL146241","U01 AA020790","U01 HL146240","K01 AI122853","U01 HL146202","U01 HL146201","U01 HL146245","UL1 TR000083","U01 AI068634","K23 EY013707","U10 EY008067","P30 AI027767","TGF-96118","CBR-94036","U54 GM133807","P30 AI027763","HCP-97105","P30 AI036219","F31 AI124794","UL1 TR000004","U24 AA020794","F31 CA247610","U01 HL146194","U01 HL146193","U01 HL146192","P30 AI050410","K01 AI093197","U10 EY008057","P30 AI027757","U01 AA013566","N02CP55504","P30 AI110527","F31 DA037788","U10 EY008052","G12 MD007583","K24 AI120834","R34 DA045592","T32 DK062707","UL1 RR024131","P30 AI094189","R24 AI067039","U01 DA036935","K24 AI065298","R01 AG053100","N01 CP001004","CBR-86906","R01 DA012568","P30 MH062246","P30 AI050409","R01 CA250851","U01 HL146333","Z01 CP010176","U01 AI069918","U54 MD007587","U01 AI069432","K24 AI118591","U01 AI069434"],"pubmed_authors":["Mathews WC","Li J","Rabkin CS","Sterling TR","Mayor AM","Napravnik S","Connor AE","D'Souza G","Gill MJ","Shiels MS","Visvanathan K","Brown TT","Althoff KN","Coburn SB","Horberg MA","Marcus JL","Silverberg MJ","Lau B","North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiology Databases to Evaluate AIDS","Moore RD"],"additional_accession":[]},"is_claimable":false,"name":"Secular Trends in Breast Cancer Risk Among Women With HIV Initiating ART in North America.","description":"<h4>Background</h4>Studies suggest lower risk of breast cancer in women with HIV versus without HIV. These estimates may be biased by lower life expectancy and younger age distribution of women with HIV. Our analysis evaluated this bias and characterized secular trends in breast cancer among women with HIV initiating antiretroviral therapy. We hypothesized breast cancer risk would increase over time as mortality decreased.<h4>Setting</h4>Women with HIV prescribed antiretroviral therapy in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) from 1997 through 2016.<h4>Methods</h4>We estimated breast cancer hazard (cause-specific hazard ratios) and cumulative incidence accounting for competing risks (subdistribution hazard ratios) to assess changes in breast cancer risk over time. This was assessed overall (1997-2016) and within/across calendar periods. Analyses were adjusted for race/ethnicity and inverse probability weighted for cohort. Cumulative incidence was graphically assessed by calendar period and race/ethnicity.<h4>Results</h4>We observed 11,587 women during 1997-2016, contributing 63 incident breast cancer diagnoses and 1,353 deaths [73,445 person-years (median follow-up = 4.5 years)]. Breast cancer cumulative incidence was 3.2% for 1997-2016. We observed no secular trends in breast cancer hazard or cumulative incidence. There were annual declines in the hazard and cumulative incidence of death (cause-specific hazard ratios and subdistribution hazard ratios: 0.89, 95% confidence interval: 0.87 to 0.91) which remained within and across calendar periods.<h4>Conclusions</h4>These findings contradict the hypothesis of increasing breast cancer risk with declining mortality over time among women with HIV, suggesting limited impact of changing mortality on breast cancer risk. Additional inquiry is merited as survival improves among women with HIV.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2025-04-04T10:17:17.356Z","creation":"2025-04-04T10:17:17.356Z"},"accession":"S-EPMC8026587","cross_references":{"pubmed":["33492023"],"doi":["10.1097/QAI.0000000000002627","10.1097/qai.0000000000002627"]}}